Clinical characteristics of patients with Crohn’s disease
| ASCA, anti-Saccharomyces cerevisiae antibodies. | |
| Sex | |
| Female | 88/161 (54.7%) |
| Reason for operation | |
| Obstruction | 62/154 (40.3%) |
| Therapy for refractory disease | 9/154 (5.8%) |
| Fistula | 45/154 (29.2%) |
| Perforation | 38/154 (24.7%) |
| Operation number | |
| 1 | 107/159 (67.3%) |
| 2 | 39/159 (24.5%) |
| 3 | 11/159 (6.9%) |
| 4 | 2/159 (1.3%) |
| Age at surgery (y) | |
| Mean (range) | 33.6 (16–66) |
| Duration of disease at surgery (y) | |
| Mean (range) | 8.8 (0–29) |
| Location of distal margin of resection | |
| Small bowel | 77/161 (47.8%) |
| Right colon | 46/161 (28.6%) |
| Left colon | 17/161 (10.6%) |
| Anus or rectum | 21/161 (13%) |
| Smoking at the time of surgery | 41/156 (26.3%) |
| ASCA | 104/158 (65.8%) |
| Previous medical therapy (n = 155) | |
| Corticosteroids | 120 (77.4%) |
| Azathioprine | 44 (28.4%) |
| Methotrexate | 9 (5.8%) |
| Infliximab | 19 (12.0%) |
| Mesalamine | 51 (32.9%) |
| Sulfasalazine | 83 (53.5%) |
| Antibiotics | 65 (41.9%) |